Evidence based medical guidelines for the treatment of type 2 diabetes mellitus focus on three areas: lifestyle changes, radical treatment of cardiovascular risk factors and normalization of blood glucose levels. Type 2 diabetes mellitus can be characterized by peripheral insulin resistance, diminished secretion of insulin of the pancreas, and increased glucose production of the liver. The therapeutic agents used to treat T2DM beneficially influence one or more of these abnormalities. Metformin belongs to the first-line treatment of T2DM, which ameliorates peripheral insulin resistance and diminishes glucose production of the liver. Further therapeutic choices are sulfonylureas, which enhance insulin secretion, alpha-glycosidase inhibitors, and thiazolidinediones. In the clinical practice of the last few years incretin mimetic compounds and DPP4 inhibitors, which enhance incretin effect, have also been administered. In order to normalize blood glucose level, drugs with different mechanism of action can be coadministered and most of them can be supplemented with insulin treatment.
|Number of pages||10|
|Publication status||Published - Dec 1 2010|
ASJC Scopus subject areas